CGXYY yields 3.21% · PFE yields 6.13%● Live data
📍 CGXYY pulled ahead of the other in Year 1
Combined, CGXYY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CGXYY + PFE for your $10,000?
China Galaxy Securities Co., Ltd. provides various financial services in the People's Republic of China. Its Securities Brokerage segment offers securities dealing and broking; margin financing to margin clients; and securities lending services. The Company's Futures Brokerage segment is involved in futures dealing and broking, futures information consulting, and training activities. Its Proprietary Trading and Other Securities Trading Services segment engages in trading of equities, bonds, funds, derivatives, and other financial products. The Company's Investment Banking segment provides corporate financial services, including equity and debt securities underwriting, and financial advisory services to institutional clients. Its Asset Management segment offers portfolio management, investment advisory, and transaction execution services. The Company's Private Equity and Alternative Investment segment provides equity investments in private companies. Its Overseas Business segment offers securities and futures brokerage, securities research, investment banking, margin financing, money lending, asset management, and insurance brokerage services. The company serves various individual and institutional clients comprising multinational corporations, medium and small-sized enterprises, high-net-worth clients, and retail clients. As of December 31, 2021, it operated through a network of 37 branch offices and 501 securities branches. The company was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China. China Galaxy Securities Co., Ltd. operates as a subsidiary of China Galaxy Financial Holdings Company Limited.
Full CGXYY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.